Glaukos (NYSE:GKOS) Price Target Raised to $240.00

Glaukos (NYSE:GKOS) had its price objective hoisted by JPMorgan Chase & Co. from $200.00 to $240.00 in a report published on Thursday morning,Benzinga reports. The firm currently has an overweight rating on the medical instruments supplier’s stock.

Several other brokerages have also weighed in on GKOS. Piper Sandler reiterated an “overweight” rating and set a $240.00 price objective (up from $195.00) on shares of Glaukos in a report on Thursday. Stifel Nicolaus boosted their target price on shares of Glaukos from $190.00 to $225.00 and gave the company a “buy” rating in a report on Thursday. Wells Fargo & Company upped their price target on shares of Glaukos from $178.00 to $226.00 and gave the stock an “overweight” rating in a research report on Thursday. Truist Financial increased their price target on shares of Glaukos from $215.00 to $255.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $216.71.

Glaukos Stock Performance

Shares of GKOS opened at $236.92 on Thursday. Glaukos has a 12-month low of $80.90 and a 12-month high of $248.75. The stock has a market cap of $14.03 billion, a P/E ratio of -80.58 and a beta of 0.69. The company has a current ratio of 4.57, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average of $173.30 and a two-hundred day moving average of $141.14.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The company had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. During the same period in the prior year, the firm earned ($0.16) EPS. The firm’s quarterly revenue was up 58.0% on a year-over-year basis. As a group, research analysts predict that Glaukos will post 0.15 EPS for the current fiscal year.

Insider Activity

In other Glaukos news, Director Gilbert H. Kliman sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total transaction of $475,000.00. Following the sale, the director owned 37,406 shares in the company, valued at $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Alex R. Thurman sold 20,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the sale, the chief financial officer directly owned 43,906 shares in the company, valued at $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 82,500 shares of company stock worth $14,862,000. 5.90% of the stock is currently owned by insiders.

Institutional Trading of Glaukos

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Provenance Wealth Advisors LLC bought a new stake in Glaukos in the 3rd quarter valued at about $44,000. Factory Mutual Insurance Co. bought a new position in Glaukos in the 3rd quarter worth about $350,000. Virtue Capital Management LLC bought a new position in Glaukos in the 3rd quarter worth about $303,000. Sumitomo Mitsui Trust Group Inc. acquired a new stake in shares of Glaukos in the third quarter valued at approximately $1,248,000. Finally, Vise Technologies Inc. acquired a new stake in shares of Glaukos in the third quarter valued at approximately $668,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Glaukos reported third-quarter revenue of approximately $211 million, up 58% year over year and well above the $168 million analyst consensus. Earnings were $0.47 per share versus expectations for a $0.10–$0.12 loss and a $0.16 loss in the prior-year quarter. Glaukos Q3 earnings and revenues surpass estimates
• Positive Sentiment: Management raised fiscal 2026 revenue guidance to $775 million–$785 million, substantially above the roughly $691.5 million consensus estimate. It also set a preliminary fiscal 2027 sales target of $1 billion, versus Wall Street expectations of about $849 million, reinforcing the growth story. Glaukos sets $1 billion 2027 sales goal
• Positive Sentiment: Analyst sentiment improved following the results. Zacks Research upgraded GKOS from “hold” to “strong buy,” while Needham raised its price target to $251 and JPMorgan lifted its target to $240, maintaining an “overweight” rating.
• Neutral Sentiment: Other firms also raised their targets, including Wells Fargo to $226, BTIG to $234 and Stifel to $225. However, each remains below the recent trading level, suggesting analysts are becoming more constructive while still seeing limited near-term upside at the current valuation.
• Negative Sentiment: The headline profit included factors that may not fully reflect recurring operating earnings. Glaukos continues to report a negative net margin, and commentary noted that underlying profitability is thinner than adjusted figures suggest. With a price-to-earnings ratio based on losses and the stock near its 52-week high, expectations and valuation remain elevated.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.